{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-151761","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.281444+00:00","generated_at":"2026-06-25T14:49:57.659220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acumen Q1 2022 net loss $9.1M; cash $216.7M, runway through 2025","bullets":["Cash, cash equivalents and marketable securities totaled $216.7M as of March 31, 2022, down from $225.9M at year-end 2021; expected to fund operations through 2025.","R&D expenses rose to $6.0M from $2.6M YoY due to ongoing Phase 1 trial (INTERCEPT-AD) of ACU193 for early Alzheimer's.","Net loss was $9.1M vs $27.0M in Q1 2021; prior-year loss included $23.2M non-cash expense from warrant/liability fair value changes.","Topline data from INTERCEPT-AD Phase 1 trial expected in first half of 2023; enrollment ongoing.","Preclinical evidence supporting ACU193's selective targeting of soluble amyloid-beta oligomers published in Frontiers in Neuroscience."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-151761","json":"https://secwatch.observer/filing/0001193125-22-151761.json","markdown":"https://secwatch.observer/filing/0001193125-22-151761.md","text":"https://secwatch.observer/filing/0001193125-22-151761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522151761/0001193125-22-151761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522151761/d357212d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T14:49:57.659220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}